发明授权
- 专利标题: Furin inhibitors
-
申请号: US17054491申请日: 2019-05-10
-
公开(公告)号: US11773078B2公开(公告)日: 2023-10-03
- 发明人: Jeffrey Michael Axten , Mui Cheung , Michael P. Demartino , Huiping Amy Guan , Yan Hu , Aaron Bayne Miller , Donghui Qin , Chengde Wu , Zhiliu Zhang , Xiaojuan Lin
- 申请人: Glaxosmithkline Intellectual Property Development Limited
- 申请人地址: GB Brentford
- 专利权人: Glaxosmithkline Intellectual Property Development Limited
- 当前专利权人: Glaxosmithkline Intellectual Property Development Limited
- 当前专利权人地址: GB Brentford
- 代理机构: Wolf, Greenfield & Sacks, P.C.
- 国际申请: PCT/EP2019/062098 2019.05.10
- 国际公布: WO2019/215341A 2019.11.14
- 进入国家日期: 2020-11-10
- 主分类号: C07D401/12
- IPC分类号: C07D401/12 ; C07D401/14 ; A61P11/00 ; C07D211/26 ; C07D487/08
摘要:
This invention relates to novel compounds according to Formula (I) which are inhibitors of furin, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of fibrotic diseases, including pulmonary fibrosis, renal fibrosis, liver fibrosis, skin fibrosis, ocular fibrosis, cardiac fibrosis, and other miscellaneous fibrotic conditions. The disclosed compounds may also be useful for treating other furin-mediated conditions, including but not limited to, hypertension, cancer, infectious diseases, and genetic disorders (e.g., cystic fibrosis (CF)), and neurodegenerative disorders.
公开/授权文献
- US20220315556A1 FURIN INHIBITORS 公开/授权日:2022-10-06
信息查询